<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40900212</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1563-258X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Wiener medizinische Wochenschrift (1946)</Title><ISOAbbreviation>Wien Med Wochenschr</ISOAbbreviation></Journal><ArticleTitle>Treatment outcomes and safety profile of SGLT2 inhibitors versus GLP-1 agonists in type&#xa0;2 diabetes mellitus : Systematic review of real-world observational studies.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10354-025-01108-5</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Several pharmacotherapies are available to treat type&#xa0;2 diabetes mellitus (T2DM) among which sodium-glucose cotransporter&#xa0;2&#xa0;inhibitors (SGLT2is) and glucagon-like peptide&#xa0;1 (GLP-1) receptor agonists are significant. The current systematic review aims to critically evaluate various clinical outcomes and safety profile of SGLT2is in comparison to GLP&#x2011;1 receptor agonists for the management of T2DM utilizing real-world clinical data.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A&#xa0;total of 22,100 research articles were extracted from several electronic databases including EMBASE, PubMed, Clinicaltrials.gov, and Cochrane Library from January 2010 to September 2024. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed to maintain consistency and transparency in research. To obtain insights from the real-world clinical data, observational studies were used for this review, excluding , randomized controlled trials.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The pooled analysis showed that risk ratio (RR) of heart failure and MACE (major cardiovascular events) or revascularization, and odds ratio (OR) of renal outcomes were slightly higher among SGLT2is (experimental) as compared to GLP&#x2011;1 agonist (control). In addition, the pooled analysis of hypoglycemic events and all-cause mortalities favored SGLT2is as compared to GLP&#x2011;1 agonist.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">SGLT2is appear to be more effective in lowering hospitalization for heart failure; GLP&#x2011;1 medication appears to be safer and more successful in treating MACE and improving renal outcomes. Occurrence of hypoglycemic events and the rate of all-cause mortality were found to be low in the SGLT2is group, which supported the clinical implication of SGLT2is.</AbstractText><CopyrightInformation>&#xa9; 2025. Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH Austria, ein Teil von Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alam</LastName><ForeName>Aftab</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6733-8311</Identifier><AffiliationInfo><Affiliation>Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, 11942, Al-Kharj, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imran</LastName><ForeName>Mohd</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6064-1040</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, College of Pharmacy, Northern Border University, Rafha, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Health Research, Northern Border University, Arar, 73213, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ur Rehman</LastName><ForeName>Zia</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-6540-7966</Identifier><AffiliationInfo><Affiliation>Health Research Centre , Jazan University, 114, Jazan, Saudi Arabia, 45142.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy , Jazan University, 114, Jazan, Saudi Arabia, 45142.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahoo</LastName><ForeName>Biswa Mohan</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0001-8822-0427</Identifier><AffiliationInfo><Affiliation>School of Pharmacy and Life Sciences, Centurion University of Technology &amp; Management, Jatni, Odisha, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahapatra</LastName><ForeName>Manoj Kumar</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Chemistry, Kanak Manjari Institute of Pharmaceutical Sciences, 769015, Rourkela, Odisha, India. manojbit07@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Therapieergebnisse und Sicherheitsprofil von SGLT2-Inhibitoren versus GLP-1-Agonisten bei Diabetes mellitus Typ&#xa0;2 : Systematische &#xdc;bersichtsarbeit zu Beobachtungsstudien aus der Praxis.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>Wien Med Wochenschr</MedlineTA><NlmUniqueID>8708475</NlmUniqueID><ISSNLinking>0043-5341</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiovascular outcomes</Keyword><Keyword MajorTopicYN="N">Glucagon-like peptide&#xa0;1 agonists</Keyword><Keyword MajorTopicYN="N">Kidney function</Keyword><Keyword MajorTopicYN="N">Real-world observational studies</Keyword><Keyword MajorTopicYN="N">Sodium&#x2013;glucose cotransporter&#xa0;2&#xa0;inhibitors</Keyword></KeywordList><CoiStatement>Conflict of interest: A.&#xa0;Alam, M.&#xa0;Imran, Z.&#xa0;ur Rehman, B.M.&#xa0;Sahoo and M.K.&#xa0;Mahapatra declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>11</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40900212</ArticleId><ArticleId IdType="doi">10.1007/s10354-025-01108-5</ArticleId><ArticleId IdType="pii">10.1007/s10354-025-01108-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmad&#xa0;E, Lim&#xa0;S, Lamptey&#xa0;R, Webb&#xa0;DR, Davies&#xa0;MJ. Type&#xa0;2 diabetes. Lancet. 2022;400(10365):1803&#x2013;20. https://doi.org/10.1016/S0140-6736(22)01655-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01655-5</ArticleId><ArticleId IdType="pubmed">36332637</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(1):S17&#x2013;S38. https://doi.org/10.2337/dc22-S002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc22-S002</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho&#xa0;NH, Shaw&#xa0;JE, Karuranga&#xa0;S, Huang&#xa0;Y, da Rocha Fernandes&#xa0;JD, Ohlrogge&#xa0;A, et&#xa0;al. IDF diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271&#x2013;81. https://doi.org/10.1016/j.diabres.2018.02.023 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2018.02.023</ArticleId><ArticleId IdType="pubmed">29496507</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain&#xa0;MJ, Al-Mamun&#xa0;M, Islam&#xa0;MR. Diabetes mellitus, the fastest growing global public health concern: early detection should be focused. Health Sci Rep. 2024;7(3):e2004. https://doi.org/10.1002/hsr2.2004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hsr2.2004</ArticleId><ArticleId IdType="pubmed">38524769</ArticleId><ArticleId IdType="pmc">10958528</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu&#xa0;R, Zhou&#xa0;S, Xia&#xa0;L, Bao&#xa0;X. Incidence, morbidity and years lived with disability due to type&#xa0;2 diabetes mellitus in 204 countries and territories: trends from 1990 to 2019. Front Endocrinol. 2022;13:905538. https://doi.org/10.3389/fendo.2022.905538 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.905538</ArticleId></ArticleIdList></Reference><Reference><Citation>Inzucchi&#xa0;SE, Bergenstal&#xa0;RM, Buse&#xa0;JB, Diamant&#xa0;M, Ferrannini&#xa0;E, Nauck&#xa0;M, et&#xa0;al. Management of hyperglycemia in type&#xa0;2 diabetes, 2015: a&#xa0;patient-centered approach: update to a&#xa0;position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140&#x2013;9. https://doi.org/10.2337/dc14-2441 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc14-2441</ArticleId><ArticleId IdType="pubmed">25538310</ArticleId></ArticleIdList></Reference><Reference><Citation>Malla&#xa0;P, Kumar&#xa0;R, Mahapatra&#xa0;MK, Kumar&#xa0;M. Ramping glucosuria for management of type&#xa0;2 diabetes mellitus: an emerging cynosure. Med Res Rev. 2014;34(6):1146&#x2013;67. https://doi.org/10.1002/med.21314 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21314</ArticleId><ArticleId IdType="pubmed">24633706</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahapatra&#xa0;MK, Karuppasamy&#xa0;M, Sahoo&#xa0;BM. Semaglutide, a&#xa0;glucagon like peptide&#x2011;1 receptor agonist with cardiovascular benefits for management of type&#xa0;2 diabetes. Rev Endocr Metab Disord. 2022;23(3):521&#x2013;39. https://doi.org/10.1007/s11154-021-09699-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11154-021-09699-1</ArticleId><ArticleId IdType="pubmed">34993760</ArticleId><ArticleId IdType="pmc">8736331</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahapatra&#xa0;MK, Karuppasamy&#xa0;M, Sahoo&#xa0;BM. Therapeutic potential of semaglutide, a&#xa0;newer GLP&#x2011;1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a&#xa0;narrative review. Pharm Res. 2022;39(6):1233&#x2013;48. https://doi.org/10.1007/s11095-022-03302-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-022-03302-1</ArticleId><ArticleId IdType="pubmed">35650449</ArticleId><ArticleId IdType="pmc">9159769</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldevila&#xa0;B, Puig-Domingo&#xa0;M. Safety and tolerability of GLP&#x2011;1 receptor agonists. Med Clin (Barc). 2014;143:35&#x2013;40. https://doi.org/10.1016/S0025-7753(14)70107-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0025-7753(14)70107-1</ArticleId><ArticleId IdType="pubmed">25437464</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso&#xa0;SP, Daniels&#xa0;GH, Brown-Frandsen&#xa0;K, Kristensen&#xa0;P, Mann&#xa0;JF, Nauck&#xa0;MA, et&#xa0;al. Liraglutide and cardiovascular outcomes in type&#xa0;2 diabetes. N&#xa0;Engl J Med. 2016;375(4):311&#x2013;22. https://doi.org/10.1056/NEJMoa1603827 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1603827</ArticleId><ArticleId IdType="pubmed">27295427</ArticleId><ArticleId IdType="pmc">4985288</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman&#xa0;B, Wanner&#xa0;C, Lachin&#xa0;JM, Fitchett&#xa0;D, Bluhmki&#xa0;E, Hantel&#xa0;S, et&#xa0;al. Empagliflozin, cardiovascular outcomes, and mortality in type&#xa0;2 diabetes. N&#xa0;Engl J Med. 2015;373(22):2117&#x2013;28. https://doi.org/10.1056/NEJMoa1504720 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1504720</ArticleId><ArticleId IdType="pubmed">26378978</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah&#xa0;SR, Najim&#xa0;NI, Abbasi&#xa0;Z, Fatima&#xa0;M, Jangda&#xa0;AA, Shahnawaz&#xa0;W, et&#xa0;al. Canagliflozin and cardiovascular disease-results of the CANVAS trial. J&#xa0;Community Hosp Intern Med Perspect. 2018;8(5):267&#x2013;8. https://doi.org/10.1080/20009666.2018.1521245 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20009666.2018.1521245</ArticleId><ArticleId IdType="pubmed">30357039</ArticleId><ArticleId IdType="pmc">6197007</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer&#xa0;CK, Ye&#xa0;C, Retnakaran&#xa0;R. Comparison of new glucose-lowering drugs for primary and secondary prevention of cardiovascular disease in type&#xa0;2 diabetes: a&#xa0;network meta-analysis of cardiovascular outcome trials. SSRN Journal. 2019; https://doi.org/10.2139/ssrn.3436269 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3436269</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann&#xa0;JFE, &#xd8;rsted&#xa0;DD, Brown-Frandsen&#xa0;K, Marso&#xa0;SP, Poulter&#xa0;NR, Rasmussen&#xa0;S, Torn&#xf8;e&#xa0;K, Zinman&#xa0;B, Buse&#xa0;JB, LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type&#xa0;2 diabetes. N&#xa0;Engl J Med. 2017;377(9):839&#x2013;48. https://doi.org/10.1056/NEJMoa1616011 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1616011</ArticleId><ArticleId IdType="pubmed">28854085</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman&#xa0;B, Nauck&#xa0;MA, Bosch-Traberg&#xa0;H, Frimer-Larsen&#xa0;H, &#xd8;rsted&#xa0;DD, Buse&#xa0;JB. Liraglutide and glycaemic outcomes in the LEADER trial. Diabetes Ther. 2018;9(6):2383&#x2013;92. https://doi.org/10.1007/s13300-018-0524-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13300-018-0524-z</ArticleId><ArticleId IdType="pubmed">30392095</ArticleId><ArticleId IdType="pmc">6250637</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire&#xa0;DK, Busui&#xa0;RP, Deanfield&#xa0;J, Inzucchi&#xa0;SE, Mann&#xa0;JFE, Marx&#xa0;N, Mulvagh&#xa0;SL, Poulter&#xa0;N, Engelmann&#xa0;MDM, Hovingh&#xa0;GK, Ripa&#xa0;MS, Gislum&#xa0;M, Brown-Frandsen&#xa0;K, Buse&#xa0;JB. Effects of oral semaglutide on cardiovascular outcomes in individuals with type&#xa0;2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: design and baseline characteristics of SOUL, a&#xa0;randomized trial. Diabetes Obes Metab. 2023;25(7):1932&#x2013;41. https://doi.org/10.1111/dom.15058 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.15058</ArticleId><ArticleId IdType="pubmed">36945734</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association. 85th&#xa0;scientific sessions. Oral semaglutide significantly improves cardiovascular outcomes in individuals with type&#xa0;2 diabetes https://professional.diabetes.org/sites/dpro/files/2025-06/ADA2025_SOULTrialPressRelease_FINAL.PDF.pdf .</Citation></Reference><Reference><Citation>Li&#xa0;C, Luo&#xa0;J, Jiang&#xa0;M, Wang&#xa0;K. The efficacy and safety of the combination therapy with GLP&#x2011;1 receptor agonists and SGLT-2&#xa0;inhibitors in type&#xa0;2 diabetes mellitus: a&#xa0;systematic review and meta-analysis. Front Pharmacol. 2022;13:838277. https://doi.org/10.3389/fphar.2022.838277 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.838277</ArticleId><ArticleId IdType="pubmed">35185588</ArticleId><ArticleId IdType="pmc">8854770</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo&#xa0;M, Gu&#xa0;J, Teng&#xa0;F, Chen&#xa0;J, Ma&#xa0;X, Chen&#xa0;Q, et&#xa0;al. The efficacy and safety of combinations of SGLT2 inhibitors and GLP&#x2011;1 receptor agonists in the treatment of type&#xa0;2 diabetes or obese adults: a&#xa0;systematic review and meta-analysis. Endocrine. 2020;67(2):294&#x2013;304. https://doi.org/10.1007/s12020-019-02175-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-019-02175-6</ArticleId><ArticleId IdType="pubmed">31900793</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelniker&#xa0;TA, Wiviott&#xa0;SD, Raz&#xa0;I, et&#xa0;al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type&#xa0;2 diabetes: a&#xa0;systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32590-X</ArticleId><ArticleId IdType="pubmed">30424892</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattar&#xa0;N, Lee&#xa0;MMY, Kristensen&#xa0;SL, et&#xa0;al. Cardiovascular, mortality, and kidney outcomes with GLP&#x2011;1 receptor agonists in patients with type&#xa0;2 diabetes: a&#xa0;systematic review and meta-analysis of randomized trials. Lancet Diabetes Endocrinol. 2021;9:653&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(21)00203-5</ArticleId><ArticleId IdType="pubmed">34425083</ArticleId></ArticleIdList></Reference><Reference><Citation>Apperloo&#xa0;E, Neuen&#xa0;BL, Fletcher&#xa0;RA, et&#xa0;al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a&#xa0;SMART&#x2011;C collaborative meta-analysis of randomized controlled trials. Lancet Diabetes Endocrinol. 2024; https://doi.org/10.1016/S2213-8587(24)00155-4 .</Citation></Reference><Reference><Citation>Neves&#xa0;JS, Borges-Canha&#xa0;M, Vasques-N&#xf3;voa&#xa0;F, et&#xa0;al. GLP&#x2011;1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type&#xa0;2 diabetes. J&#xa0;Am Coll Cardiol. 2023;82:517&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.05.048</ArticleId><ArticleId IdType="pubmed">37532422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervantes&#xa0;CE. SGLT2 inhibitors and GLP&#x2011;1 receptor agonists: the definitive combination? Lancet Diabetes Endocrinol. 2024;12(8):507&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(24)00183-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang&#xa0;Y, Xia&#xa0;C, Li&#xa0;M, Xu&#xa0;G. Comparison of the effects of SGLT-2i versus GLP-1RA on cardiovascular and renal outcomes in patients with type&#xa0;2 diabetes, based on baseline renal function. Diabetes. 2025;74:672&#x2013;81. https://doi.org/10.2337/db24-0688 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db24-0688</ArticleId><ArticleId IdType="pubmed">39932725</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori&#xa0;T, Kuss&#xa0;O, Mader&#xa0;JK, Seufert&#xa0;J, Holl&#xa0;RW, Lanzinger&#xa0;S, Grimsmann&#xa0;JM. SGLT2 inhibitors or GLP&#x2011;1 receptor agonists? Development of a&#xa0;personalized treatment algorithm for individuals with type&#xa0;2 diabetes. Diabetes. 2025;74(1):898. https://doi.org/10.2337/db25-898-P .</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db25-898-P</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025;48(1):S181&#x2013;S206. https://doi.org/10.2337/dc25-S009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc25-S009</ArticleId></ArticleIdList></Reference><Reference><Citation>Du&#xa0;L, Li&#xa0;Z, Lan&#xa0;P, Huang&#xa0;H, Cheng&#xa0;W. Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status. Front Cardiovasc Med. 2022;9:1011535. https://doi.org/10.3389/fcvm.2022.1011535 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.1011535</ArticleId><ArticleId IdType="pubmed">36148068</ArticleId><ArticleId IdType="pmc">9485680</ArticleId></ArticleIdList></Reference><Reference><Citation>Kani&#xa0;R, Watanabe&#xa0;A, Miyamoto&#xa0;Y, Ejiri&#xa0;K, Iwagami&#xa0;M, Takagi&#xa0;H, Slipczuk&#xa0;L, Tsugawa&#xa0;Y, Aikawa&#xa0;T, Kuno&#xa0;T. Comparison of effectiveness among different sodium-glucose cotransoporter&#x2011;2 inhibitors according to underlying conditions: a&#xa0;network meta-analysis of randomized controlled trials. J&#xa0;Am Heart Assoc. 2024;13(3):e31805. https://doi.org/10.1161/JAHA.123.031805 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.123.031805</ArticleId><ArticleId IdType="pubmed">38293914</ArticleId><ArticleId IdType="pmc">11056162</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheen&#xa0;AJ. Cardiovascular outcome studies in type&#xa0;2 diabetes: comparison between SGLT2 inhibitors and GLP&#x2011;1 receptor agonists. Diabetes Res Clin Pract. 2018;143:88&#x2013;100. https://doi.org/10.1016/j.diabres.2018.06.008 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2018.06.008</ArticleId><ArticleId IdType="pubmed">29944969</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan&#xa0;HU, Akhtar&#xa0;B, Singla&#xa0;B, Mughal&#xa0;HMF, Hamid&#xa0;A, Khan&#xa0;ZU, Ismail&#xa0;S, Sana&#xa0;M, Khaliq&#xa0;M. Comparative effectiveness of sodium-glucose cotransporter&#x2011;2 inhibitors versus glucagon-like peptide&#x2011;1 receptor agonists in reducing cardiovascular events in patients with type&#xa0;2 diabetes. Cureus. 2025;17(5):e84137. https://doi.org/10.7759/cureus.84137 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.84137</ArticleId><ArticleId IdType="pubmed">40524985</ArticleId><ArticleId IdType="pmc">12168791</ArticleId></ArticleIdList></Reference><Reference><Citation>Htoo&#xa0;PT, Tesfaye&#xa0;H, Schneeweiss&#xa0;S, et&#xa0;al. Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide&#x2011;1 receptor agonists: final-year results from the EMPRISE study. Cardiovasc Diabetol. 2024;23(1):57. https://doi.org/10.1186/s12933-024-02150-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-024-02150-0</ArticleId><ArticleId IdType="pubmed">38331813</ArticleId><ArticleId IdType="pmc">10854040</ArticleId></ArticleIdList></Reference><Reference><Citation>EMPRISE: empagliflozin bests GLP&#x2011;1 Ras, DPP&#x2011;4 inhibitors for reducing heart failure hospitalizations https://www.hcplive.com/view/emprise-empagliflozin-bests-glp-1-ras-dpp-4-inhibitors-for-reducing-heart-failure-hospitalizations .</Citation></Reference><Reference><Citation>Yamada&#xa0;T, Wakabayashi&#xa0;M, Bhalla&#xa0;A, Chopra&#xa0;N, Miyashita&#xa0;H, Mikami&#xa0;T, et&#xa0;al. Cardiovascular and renal outcomes with SGLT-2&#xa0;inhibitors versus GLP&#x2011;1 receptor agonists in patients with type&#xa0;2 diabetes mellitus and chronic kidney disease: a&#xa0;systematic review and network meta-analysis. Cardiovasc Diabetol. 2021;20(1):14. https://doi.org/10.1186/s12933-020-01197-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-020-01197-z</ArticleId><ArticleId IdType="pubmed">33413348</ArticleId><ArticleId IdType="pmc">7792332</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer&#xa0;SC, Tendal&#xa0;B, Mustafa&#xa0;RA, Vandvik&#xa0;PO, Li&#xa0;S, Hao&#xa0;Q, et&#xa0;al. Sodium-glucose cotransporter protein&#x2011;2 (SGLT-2) inhibitors and glucagon-like peptide&#x2011;1 (GLP-1) receptor agonists for type&#xa0;2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. https://doi.org/10.1136/bmj.m4573 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4573</ArticleId><ArticleId IdType="pubmed">33441402</ArticleId><ArticleId IdType="pmc">7804890</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher&#xa0;D, Shamseer&#xa0;L, Clarke&#xa0;M, Ghersi&#xa0;D, Liberati&#xa0;A, Petticrew&#xa0;M, et&#xa0;al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. https://doi.org/10.1186/2046-4053-4-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2046-4053-4-1</ArticleId><ArticleId IdType="pubmed">25554246</ArticleId><ArticleId IdType="pmc">4320440</ArticleId></ArticleIdList></Reference><Reference><Citation>Methley&#xa0;AM, Campbell&#xa0;S, Chew-Graham&#xa0;C, McNally&#xa0;R, Cheraghi-Sohi&#xa0;S. PICO, PICOS and SPIDER: a&#xa0;comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14:579. https://doi.org/10.1186/s12913-014-0579-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-014-0579-0</ArticleId><ArticleId IdType="pubmed">25413154</ArticleId><ArticleId IdType="pmc">4310146</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo&#xa0;CK&#x2011;L, Mertz&#xa0;D, Loeb&#xa0;M. Newcastle-Ottawa Scale: comparing reviewers&#x2019; to authors&#x2019; assessments. BMC Med Res Methodol. 2014;14:45. https://doi.org/10.1186/1471-2288-14-45 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-45</ArticleId><ArticleId IdType="pubmed">24690082</ArticleId><ArticleId IdType="pmc">4021422</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins&#xa0;JP, Altman&#xa0;DG. Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions: Cochrane book series. 2008. pp.&#xa0;1&#x2013;73.</Citation></Reference><Reference><Citation>Sedgwick&#xa0;P. Meta-analyses: tests of heterogeneity. BMJ. 2012;344:e3971. https://doi.org/10.1136/bmj.e3971 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e3971</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks JJ, Higgins JP. Statistical algorithms in review manager 5. 2010. https://training.cochrane.org/handbook/statistical-methods-revman5 .</Citation></Reference><Reference><Citation>Edmonston&#xa0;D, Mulder&#xa0;H, Lydon&#xa0;E, Chiswell&#xa0;K, Lampron&#xa0;Z, Shay&#xa0;C, et&#xa0;al. Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP&#x2011;1 receptor agonists in type&#xa0;2 diabetes. J&#xa0;Am Coll Cardiol. 2024;84(8):696&#x2013;708. https://doi.org/10.1016/j.jacc.2024.06.016 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2024.06.016</ArticleId><ArticleId IdType="pubmed">39142723</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie&#xa0;Y, Bowe&#xa0;B, Gibson&#xa0;AK, McGill&#xa0;JB, Maddukuri&#xa0;G, Yan&#xa0;Y, et&#xa0;al. Comparative effectiveness of SGLT2 inhibitors, GLP&#x2011;1 receptor agonists, DPP-4&#xa0;inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a&#xa0;target trial using health care databases. Diabetes Care. 2020;43(11):2859&#x2013;69. https://doi.org/10.2337/dc20-1890 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-1890</ArticleId><ArticleId IdType="pubmed">32938746</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutz&#xa0;A, Kim&#xa0;DH, Wexler&#xa0;DJ, Liu&#xa0;J, Schneeweiss&#xa0;S, Glynn&#xa0;RJ, et&#xa0;al. Comparative cardiovascular effectiveness and safety of SGLT-2&#xa0;inhibitors, GLP&#x2011;1 receptor agonists, and DPP-4&#xa0;inhibitors according to frailty in type&#xa0;2 diabetes. Diabetes Care. 2023;46(11):2004&#x2013;14. https://doi.org/10.2337/dc23-0671 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc23-0671</ArticleId><ArticleId IdType="pubmed">37677118</ArticleId><ArticleId IdType="pmc">10620535</ArticleId></ArticleIdList></Reference><Reference><Citation>Baviera&#xa0;M, Foresta&#xa0;A, Colacioppo&#xa0;P, Macaluso&#xa0;G, Roncaglioni&#xa0;MC, Tettamanti&#xa0;M, et&#xa0;al. Effectiveness and safety of GLP&#x2011;1 receptor agonists versus SGLT-2&#xa0;inhibitors in type&#xa0;2 diabetes: an Italian cohort study. Cardiovasc Diabetol. 2022;21(1):162. https://doi.org/10.1186/s12933-022-01572-y .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01572-y</ArticleId><ArticleId IdType="pubmed">35999556</ArticleId><ArticleId IdType="pmc">9400295</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadini&#xa0;GP, Longato&#xa0;E, Morieri&#xa0;ML, Bonora&#xa0;E, Consoli&#xa0;A, Fattor&#xa0;B, et&#xa0;al. Comparative renal outcomes of matched cohorts of patients with type&#xa0;2 diabetes receiving SGLT2 inhibitors or GLP&#x2011;1 receptor agonists under routine care. Diabetologia. 2024;67(11):2585&#x2013;97. https://doi.org/10.1007/s00125-024-06251-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-024-06251-z</ArticleId><ArticleId IdType="pubmed">39177691</ArticleId><ArticleId IdType="pmc">11519175</ArticleId></ArticleIdList></Reference><Reference><Citation>Longato&#xa0;E, Di Camillo&#xa0;B, Sparacino&#xa0;G, Gubian&#xa0;L, Avogaro&#xa0;A, Fadini&#xa0;GP. Cardiovascular outcomes of type&#xa0;2 diabetic patients treated with SGLT-2&#xa0;inhibitors versus GLP&#x2011;1 receptor agonists in real-life. BMJ Open Diabetes Res Care. 2020;8(1):e1451. https://doi.org/10.1136/bmjdrc-2020-001451 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2020-001451</ArticleId><ArticleId IdType="pubmed">32591373</ArticleId><ArticleId IdType="pmc">7319723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao&#xa0;F&#x2011;Y, Tan&#xa0;EC&#x2011;H, Meng&#xa0;L&#x2011;C, Lin&#xa0;Y&#x2011;C, Chen&#xa0;H&#x2011;M, Guan&#xa0;S&#x2011;T, et&#xa0;al. Effect of frailty on effectiveness and safety of GLP&#x2011;1 receptor agonists versus SGLT2 inhibitors in people with type&#xa0;2 diabetes in Taiwan: a&#xa0;retrospective, nationwide, longitudinal study. Lancet Healthy Longev. 2024;5(9):100621. https://doi.org/10.1016/j.lanhl.2024.07.004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanhl.2024.07.004</ArticleId><ArticleId IdType="pubmed">39284334</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugner&#xa0;M, Sattar&#xa0;N, Miftaraj&#xa0;M, Ekelund&#xa0;J, Franz&#xe9;n&#xa0;S, Svensson&#xa0;A&#x2011;M, et&#xa0;al. Cardiorenal and other diabetes related outcomes with SGLT-2&#xa0;inhibitors compared to GLP&#x2011;1 receptor agonists in type&#xa0;2 diabetes: nationwide observational study. Cardiovasc Diabetol. 2021;20(1):67. https://doi.org/10.1186/s12933-021-01258-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01258-x</ArticleId><ArticleId IdType="pubmed">33752680</ArticleId><ArticleId IdType="pmc">7983265</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xf8;rgaard&#xa0;CH, Starkopf&#xa0;L, Gerds&#xa0;TA, Vestergaard&#xa0;P, Bonde&#xa0;AN, Fosb&#xf8;l&#xa0;E, et&#xa0;al. Cardiovascular outcomes with GLP&#x2011;1 receptor agonists vs. SGLT-2&#xa0;inhibitors in patients with type&#xa0;2 diabetes. Eur Heart J Cardiovasc Pharmacother. 2022;8(6):549&#x2013;56. https://doi.org/10.1093/ehjcvp/pvab053 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvab053</ArticleId><ArticleId IdType="pubmed">34215881</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellana&#xa0;M, Cignarelli&#xa0;A, Brescia&#xa0;F, Perrini&#xa0;S, Natalicchio&#xa0;A, Laviola&#xa0;L, et&#xa0;al. Efficacy and safety of GLP&#x2011;1 receptor agonists as add-on to SGLT2 inhibitors in type&#xa0;2 diabetes mellitus: a&#xa0;meta-analysis. Sci Rep. 2019;9(1):19351. https://doi.org/10.1038/s41598-019-55524-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-55524-w</ArticleId><ArticleId IdType="pubmed">31852920</ArticleId><ArticleId IdType="pmc">6920368</ArticleId></ArticleIdList></Reference><Reference><Citation>Jendle&#xa0;J, Grunberger&#xa0;G, Blevins&#xa0;T, Giorgino&#xa0;F, Hietpas&#xa0;RT, Botros&#xa0;FT. Efficacy and safety of dulaglutide in the treatment of type&#xa0;2 diabetes: a&#xa0;comprehensive review of the dulaglutide clinical data focusing on the AWARD phase&#xa0;3 clinical trial program. Diabetes Metab Res Rev. 2016;32(8):776&#x2013;90. https://doi.org/10.1002/dmrr.2810 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.2810</ArticleId><ArticleId IdType="pubmed">27102969</ArticleId></ArticleIdList></Reference><Reference><Citation>Menne&#xa0;J, Dumann&#xa0;E, Haller&#xa0;H, Schmidt&#xa0;BM. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a&#xa0;systematic review and meta-analysis. PLoS Med. 2019;16(12):e1002983. https://doi.org/10.1371/journal.pmed.1002983 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002983</ArticleId><ArticleId IdType="pubmed">31815931</ArticleId><ArticleId IdType="pmc">6901179</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuersun&#xa0;A, Hou&#xa0;G, Cheng&#xa0;G. Efficacy and safety of the combination or monotherapy with GLP&#x2011;1 receptor agonists and SGLT-2&#xa0;inhibitors in type&#xa0;2 diabetes mellitus: an update systematic review and meta-analysis. Am J Med Sci. 2024;368(6):579&#x2013;88. https://doi.org/10.1016/j.amjms.2024.07.011 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2024.07.011</ArticleId><ArticleId IdType="pubmed">38977245</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantsiou&#xa0;C, Karagiannis&#xa0;T, Kakotrichi&#xa0;P, Malandris&#xa0;K, Avgerinos&#xa0;I, Liakos&#xa0;A, et&#xa0;al. Glucagon-like peptide&#x2011;1 receptor agonists and sodium-glucose co-transporter-2&#xa0;inhibitors as combination therapy for type&#xa0;2 diabetes: a&#xa0;systematic review and meta-analysis. Diabetes Obes Metab. 2020;22(10):1857&#x2013;68. https://doi.org/10.1111/dom.14108 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14108</ArticleId><ArticleId IdType="pubmed">32476254</ArticleId></ArticleIdList></Reference><Reference><Citation>Consoli&#xa0;A, Formoso&#xa0;G, Baldassarre&#xa0;MPA, Febo&#xa0;F. A&#xa0;comparative safety review between GLP&#x2011;1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opin Drug Saf. 2018;17(3):293&#x2013;302. https://doi.org/10.1080/14740338.2018.1428305 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2018.1428305</ArticleId><ArticleId IdType="pubmed">29334278</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandker TA. Relationship between SGLT2 inhibitor use and risk of lower limb amputations: a&#xa0;pharmacovigilance study: Brac University. 2023. https://dspace.bracu.ac.bd/xmlui/bitstream/handle/10361/22046/19146015_PHR.pdf?sequence=1&amp;isAllowed=y .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>